06 May 2015, Wednesday, 15:01
UFA, 6 May 2015. /Bashinform News Agency, Gulfiya Akulova/. Ufa branch of the research and production association "Microgen" completes clinical trials of the first domestic analogue of botox to restore patients after stroke.
Development of the Relatoks drug began in 2001. Modern technology to ensure high quality and safety of the drug was used while its creation. The advantage of the drug is that it is made under full production cycle from Russian raw materials, the company reported. Now there are similar drugs only of foreign production in the domestic market.
Russian equivalent of Botox can now be used not only in cosmetology. The enlarged indications for use allow administering the drug in treatment of patients with hands spasticity after ischemic stroke. Also, the company investigated a possibility of using the drug in complex treatment of children with spastic forms of cerebral palsy.
"Every year in Russia, the number of stroke patients reaches 400 thousand people. Spasticity develops in one-third of patients — a complex of symptoms characterized by increased muscle tone. A major achievement in treatment and rehabilitation of patients with post-stroke spasticity were the data on high efficiency of botulinum toxin type A drugs", the press service of " Microgen" informs.
The drug helps to relax the muscles and restore full motion after a stroke. In Russia, this method is already implemented in practice by many institutions. Ufa branch of the company is planning to complete the study by August this year.
The research and production association "Microgen" was established in 2003. The main activity of the company is development, production and sale of immunobiological drugs.